var data={"title":"Atovaquone and proguanil: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Atovaquone and proguanil: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5680?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=atovaquone-and-proguanil-drug-information\" class=\"drug drug_general\">see &quot;Atovaquone and proguanil: Drug information&quot;</a> and <a href=\"topic.htm?path=atovaquone-and-proguanil-patient-drug-information\" class=\"drug drug_patient\">see &quot;Atovaquone and proguanil: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137595\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Malarone&reg;</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137596\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Malarone&reg;;</li>\n      <li>Malarone&reg; Pediatric</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F999503\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antimalarial Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F999544\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=atovaquone-and-proguanil-drug-information\" class=\"drug drug_general\">see &quot;Atovaquone and proguanil: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;\">Pediatric: <b>Note: </b>Tablets are available in different strengths (pediatric and adult tablets) and both may be used in pediatric patients depending upon patient weight; use extra precaution</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Malaria; prevention </b>(<i>Yellow Book</i> [CDC 2018])<b>:</b> Infants, Children, and Adolescents: Begin 1 to 2 days prior to entering a malaria-endemic area, continue throughout the stay and for 7 days after leaving area: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">5 to 8 kg: Pediatric tablet (62.5 mg atovaquone/25 mg proguanil per tablet): 31.25 mg atovaquone/12.5 mg proguanil (<sup>1</sup>/<sub>2</sub> tablet) once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;8 to 10 kg: Pediatric tablet (62.5 mg atovaquone/25 mg proguanil per tablet): 46.88 mg atovaquone/18.75 mg proguanil (<sup>3</sup>/<sub>4</sub> tablet) once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;10 to 20 kg: Pediatric tablet (62.5 mg atovaquone/25 mg proguanil per tablet): 62.5 mg atovaquone/25 mg proguanil (1 tablet) once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;20 to 30 kg: Pediatric tablet (62.5 mg atovaquone/25 mg proguanil per tablet): 125 mg atovaquone/50 mg proguanil (2 tablets) once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;30 to 40 kg: Pediatric tablet (62.5 mg atovaquone/25 mg proguanil per tablet): 187.5 mg atovaquone/75 mg proguanil (3 tablets) once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;40 kg: Adult tablet (250 mg atovaquone/100 mg proguanil per tablet): 250 mg atovaquone/100 mg proguanil (1 tablet) once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Malaria; treatment, uncomplicated <i>P. falciparum or P. vivax</i></b> (CDC 2013): Infants, Children, and Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">5 to 8 kg: Pediatric tablet (62.5 mg atovaquone/25 mg proguanil per tablet): 125 mg atovaquone/50 mg proguanil (2 tablets) once daily for 3 doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">9 to 10 kg: Pediatric tablet (62.5 mg atovaquone/25 mg proguanil per tablet): 187.5 mg atovaquone/75 mg proguanil (3 tablets) once daily for 3 doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">11 to 20 kg: Adult tablet (250 mg atovaquone/100 mg proguanil per tablet): 250 mg atovaquone/100 mg proguanil (1 tablet) once daily for 3 doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">21 to 30 kg: Adult tablet (250 mg atovaquone/100 mg proguanil per tablet): 500 mg atovaquone/proguanil/200 mg proguanil (2 tablets) once daily for 3 doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">31 to 40 kg: Adult tablet (250 mg atovaquone/100 mg proguanil per tablet): 750 mg atovaquone/300 mg proguanil (3 tablets) once daily for 3 doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;40 kg: Adult tablet (250 mg atovaquone/100 mg proguanil per tablet): 1,000 mg atovaquone/400 mg proguanil (4 tablets) once daily for 3 doses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Malaria, prevention</b>: Atovaquone/proguanil 250 mg/100 mg once daily; start 1 to 2 days prior to entering a malaria-endemic area, continue throughout the stay and for 7 days after leaving area</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Malaria; acute, treatment</b>: Atovaquone/proguanil 1,000 mg/400 mg as a single dose, once daily for 3 consecutive days. <b>Note:</b> Consultants recommend dividing the daily dose in 2 to decrease nausea and vomiting.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> All patients: Should not be used as prophylaxis in severe renal impairment (CrCl &lt;30 mL/minute) (<i>Yellow Book</i> [CDC 2018]). For treatment of malaria, alternative regimens should be used in patients with CrCl &lt;30 mL/minute unless benefits outweigh the risks. No dosage adjustment required in mild to moderate renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> No dosage adjustment required in mild to moderate hepatic impairment. No data available for use in severe hepatic impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137574\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Malarone: Atovaquone 250 mg and proguanil hydrochloride 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Generic: Atovaquone 250 mg and proguanil hydrochloride 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, Oral [pediatric]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Malarone: Atovaquone 62.5 mg and proguanil hydrochloride 25 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Generic: Atovaquone 62.5 mg and proguanil hydrochloride 25 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137560\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F999554\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer with food or milk at the same time each day. If vomiting occurs within 30 minutes of administration, repeat the dose. Tablets are not palatable if chewed due to bitter taste. For children who have difficulty swallowing tablets, tablets may be crushed and mixed with condensed milk just prior to administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137590\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F999504\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Prevention (FDA approved in pediatric patients &gt;11 kg and adults) or treatment (FDA approved in pediatric patients &ge;5 kg and adults) of acute, uncomplicated <i>P. falciparum</i> malaria, including chloroquine-resistant <i>P. falciparum</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28800043\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Malarone may be confused with mefloquine</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137619\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">The following adverse reactions were reported in patients being treated for malaria. When used for prophylaxis, reactions are similar to those seen with placebo.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Central nervous system: Dizziness, headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, anorexia, diarrhea, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum ALT (increased liver function test values typically normalized after ~ 4 weeks), increased serum AST (increased liver function test values typically normalized after ~4 weeks)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anaphylaxis (rare), anemia (rare), angioedema, cholestasis, erythema multiforme (rare), hallucination, hepatic failure (case report), hepatitis (rare), neutropenia, pancytopenia (with severe renal impairment), psychotic reaction (rare), seizure (rare), skin photosensitivity, skin rash, Stevens-Johnson syndrome (rare), stomatitis, urticaria, vasculitis (rare)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137580\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to atovaquone, proguanil, or any component of the formulation; prophylactic use in severe renal impairment (CrCl &lt;30 mL/minute)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137564\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse events:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic effects: Increased transaminase levels and hepatitis have been reported with prophylactic use; single case report of hepatic failure requiring transplantation documented. Monitor closely and use caution in patients with existing hepatic impairment. Elevations in AST/ALT may persist for up to 4 weeks following treatment (Looareesuwan, 1999).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Diarrhea/vomiting: Absorption of atovaquone may be decreased in patients who have diarrhea or vomiting; monitor closely and consider use of an antiemetic. If severe, consider use of an alternative antimalarial.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Malaria: Appropriate use: Not indicated for cerebral malaria or other severe manifestations of complicated malaria. Delayed cases of <i>P. falciparum</i> malaria may occur after stopping prophylaxis; travelers returning from endemic areas who develop febrile illnesses should be evaluated for malaria. Recrudescent infections or infections following prophylaxis with this agent should be treated with alternative agent(s). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with preexisting renal disease. May use with caution for treatment of malaria in patients with severe renal impairment (CrCl &lt;30 mL/minute) if benefit outweighs risk. Contraindicated for prophylactic use in severe renal impairment due to the risk of pancytopenia in patients with severe renal impairment treated with proguanil.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Obesity: Treatment failures have been reported in patients &gt;100 kg (case reports); follow-up monitoring is recommended (Durand, 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137609\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137569\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=15548&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Antihepaciviral Combination Products: May decrease the serum concentration of Proguanil.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Phenothiazines): Antimalarial Agents may increase the serum concentration of Antipsychotic Agents (Phenothiazines). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Artemether: May enhance the adverse/toxic effect of Antimalarial Agents. Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Systemic): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Systemic). Specifically, concomitant use of antimalarial agents with dapsone may increase the risk of hemolytic reactions. Dapsone (Systemic) may enhance the adverse/toxic effect of Antimalarial Agents. Specifically, concomitant use of dapsone with antimalarial agents may increase the risk for hemolytic reactions.  Management: Closely monitor patients for signs/symptoms of hemolytic reactions with concomitant use of dapsone and antimalarial agents, particularly in patients deficient in glucose-6-phosphate dehydrogenase (G6PD), methemoglobin reductase, or with hemoglobin M.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Topical): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Topical). Specifically, the risk of hemolytic reactions may be increased.  Management: Closely monitor for signs/symptoms of hemolytic reactions with concomitant use of topical dapsone and antimalarial agents. Patients with glucose-6-phosphate dehydrogenase deficiency may be at particularly high risk for adverse hematologic effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efavirenz: May decrease the serum concentration of Atovaquone. Management: Consider alternatives to the use of atovaquone with efavirenz when possible.  If this combination must be used, monitor for evidence of reduced atovaquone clinical effectiveness.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etoposide: Atovaquone may increase the serum concentration of Etoposide.  Management: Consider separating the administration of atovaquone and etoposide by at least 1 to 2 days.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etoposide Phosphate: Atovaquone may increase the serum concentration of Etoposide Phosphate.  Management: Consider separating the administration of atovaquone and etoposide by at least 1 to 2 days.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indinavir: Atovaquone may decrease the serum concentration of Indinavir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumefantrine: Antimalarial Agents may enhance the adverse/toxic effect of Lumefantrine.  Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: May decrease the serum concentration of Atovaquone. Management: Consider alternatives to metoclopramide when possible; atovaquone should only be used with metoclopramide if no other antiemetics are available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pyrimethamine: May enhance the adverse/toxic effect of Proguanil.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May decrease the serum concentration of Atovaquone.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May decrease the serum concentration of Atovaquone.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracycline: May decrease the serum concentration of Atovaquone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Proguanil may diminish the therapeutic effect of Typhoid Vaccine. This applies only to the oral (live) typhoid vaccine.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with proguanil. When possible, proguanil should not be started within 10 days of the last vaccine dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Warfarin: Proguanil may enhance the anticoagulant effect of Warfarin. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137591\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Atovaquone taken with dietary fat significantly increases the rate and extent of absorption; AUC is increased 2-3 times and C<sub>max</sub> is increased 5 times as compared to administration during a fasted state. Management: Administer with food or milk-based drink at the same time each day.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137571\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137582\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed with the combination of atovaquone/proguanil in animal reproduction studies. The pharmacokinetics of atovaquone and proguanil may be altered during pregnancy (Wilby 2011). Malaria infection in pregnant women may be more severe than in nonpregnant women. Because <i>P. falciparum</i> malaria can cause maternal death and fetal loss, pregnant women traveling to malaria-endemic areas must use personal protection against mosquito bites. Atovaquone/proguanil may be used as an alternative treatment of malaria in pregnant women; consult current CDC guidelines (CDC 2013). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137563\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Atovaquone: Selectively inhibits parasite mitochondrial electron transport. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Proguanil: The metabolite cycloguanil inhibits dihydrofolate reductase, disrupting deoxythymidylate synthesis. Together, atovaquone/cycloguanil affect the erythrocytic and exoerythrocytic stages of development.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137579\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Atovaquone: The rate and extent of absorption is increased when administered with dietary fat. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Proguanil: Extensive </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Atovaquone: Children and Adults: ~8.8 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Proguanil: Children &gt;15 years and Adults and 31-110 kg: 1617-2502 L; Pediatric patients &le;15 years and 11-56 kg: 462-966 L; concentrated in erythrocytes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Atovaquone: &gt;99%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Proguanil: 75%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Proguanil: Hepatic to active metabolites, cycloguanil (via CYP2C19) and 4-chlorophenylbiguanide</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Atovaquone/proguanil: 23% when administered with food</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Atovaquone: 2-3 days (adults), 1-2 days (children)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Proguanil: 12-21 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Atovaquone: Feces (&gt;94% as unchanged drug); urine (&lt;0.6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Proguanil: Urine (40% to 60%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137581\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Atovaquone-Proguanil HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">62.5-25 mg (100): $253.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250-100 mg (100): $714.71</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Malarone Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">62.5-25 mg (100): $298.70</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250-100 mg (24): $197.76</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137584\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Malanil (TH, ZW);</li>\n      <li>Malarone (AT, AU, BB, BE, BH, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HN, IE, IL, IS, IT, JO, JP, KR, KW, LT, LU, MT, MY, NL, NO, NZ, PE, PL, PT, QA, SA, SE, SG, SI, SK);</li>\n      <li>Reprapog (MT)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Boggild AK, Parise ME, Lewis LS, et al, &ldquo;Atovaquone-Proguanil: Report From The CDC Expert Meeting On Malaria Chemoprophylaxis (II),&rdquo; <i>Am J Trop Med Hyg</i>, 2007, 76(2):208-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atovaquone-and-proguanil-pediatric-drug-information/abstract-text/17297027/pubmed\" target=\"_blank\" id=\"17297027\">17297027</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,&quot; <i>MMWR Recomm Rep</i>, 2009, 58(RR-11):1-166.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atovaquone-and-proguanil-pediatric-drug-information/abstract-text/19730409/pubmed\" target=\"_blank\" id=\"19730409\">19730409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &ldquo;Guidelines for Treatment of Malaria in the United States.&rdquo; Available at <a href=\"http://www.cdc.gov/malaria/resources/pdf/treatmenttable.pdf\" target=\"_blank\">http://www.cdc.gov/malaria/resources/pdf/treatmenttable.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). <i>Infectious Disease Related to Travel - Malaria</i>. Available at <a href=\"https://wwwnc.cdc.gov/travel/yellowbook/2018/infectious-diseases-related-to-travel/malaria#5217\" target=\"_blank\">https://wwwnc.cdc.gov/travel/yellowbook/2018/infectious-diseases-related-to-travel/malaria#5217</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &ldquo;Treatment of Malaria (Guidelines for Clinicians).&rdquo; Available at <a href=\"http://www.cdc.gov/malaria/resources/pdf/clinicalguidance.pdf\" target=\"_blank\">http://www.cdc.gov/malaria/resources/pdf/clinicalguidance.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Durand R, Prendki V, Cailhol J, et al, &ldquo;<i>Plasmodium falciparum</i> Malaria and Atovaquone-Proguanil Treatment Failure,&rdquo; <i>Emerg Infect Dis</i>, 2008, 14(2):320-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atovaquone-and-proguanil-pediatric-drug-information/abstract-text/18258131/pubmed\" target=\"_blank\" id=\"18258131\">18258131</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Looareesuwan S, Wilairatana P, Chalermarut K, et al. Efficacy and safety of atovaquone/proguanil compared with mefloquine for treatment of acute <i>Plasmodium falciparum</i> malaria in Thailand. <i>Am J Trop Med Hyg</i>. 1999;60(4):526-532.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atovaquone-and-proguanil-pediatric-drug-information/abstract-text/10348224/pubmed\" target=\"_blank\" id=\"10348224\">10348224</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Malarone (atovaquone and proguanil) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilby KJ, Ensom MH. Pharmacokinetics of antimalarials in pregnancy: a systematic review. <i>Clin Pharmacokinet</i>. 2011;50(11):705-723.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atovaquone-and-proguanil-pediatric-drug-information/abstract-text/21973268 /pubmed\" target=\"_blank\" id=\"21973268 \">21973268 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 15548 Version 108.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F137595\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F137596\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F999503\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F999544\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F137574\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F137560\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F999554\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F137590\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F999504\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F28800043\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F137619\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F137580\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F137564\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F137609\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F137569\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F137591\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F137571\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F137582\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F137563\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F137579\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F137581\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F137584\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/15548|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=atovaquone-and-proguanil-drug-information\" class=\"drug drug_general\">Atovaquone and proguanil: Drug information</a></li><li><a href=\"topic.htm?path=atovaquone-and-proguanil-patient-drug-information\" class=\"drug drug_patient\">Atovaquone and proguanil: Patient drug information</a></li></ul></div></div>","javascript":null}